Combinations With Lenvatinib in Patients With Metastatic Chromophobe Renal Cell Carcinoma: a Phase 2 Study. (ChromoKey)
An Open-label, Multicenter, Phase 2 Study of First-line Lenvatinib Plus Pembrolizumab and Later-line Lenvatinib Plus Everolimus in Patients With Metastatic Chromophobe Renal Cell Carcinoma.
Chromophobe renal cell carcinoma (chRCC) accounts for approximately 5% of RCC cases and has distinct morphological and molecular features. However, advanced chRCC follows an aggressive clinical course and responds poorly to standard regimens developed for clear cell RCC.
Lenvatinib plus everolimus (LEN+EVE) has demonstrated clinical activity in clear cell RCC (Study 205), with responses also reported in non-clear cell subtypes, including chRCC. Lenvatinib plus pembrolizumab (LEN+PEMBRO) demonstrated a high objective response rate (ORR) in KEYNOTE-B61, including in the chRCC subgroup.
These findings support conducting a prospective phase 2 study specifically dedicated to this rare subtype to provide direct evidence of the efficacy and safety of these two active combinations.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
ChromoKey is a prospective, open-label, multicenter, two-cohort, non-randomized phase 2 study evaluating the efficacy and safety of first-line lenvatinib plus pembrolizumab (Cohort A) and later-line lenvatinib plus everolimus (Cohort B) in patients with metastatic chromophobe renal cell carcinoma (chRCC).
The study enrolls 40 patients across two independent cohorts, with 20 patients in each cohort. Eligible patients are adults with histologically confirmed metastatic chRCC, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3, and measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients from all International Metastatic RCC Database Consortium (IMDC) risk groups are eligible.
Cohort A includes patients who have received no previous systemic therapy for metastatic disease. Patients receive lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks.
Cohort B includes patients whose disease progresses following previous systemic therapy and who have not previously received lenvatinib. Patients receive lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily. Treatment continues until disease progression or unacceptable toxicity.
The primary endpoint is the objective response rate in each cohort, defined as the proportion of patients achieving a complete or partial response according to RECIST version 1.1.
Secondary endpoints include progression-free survival, overall survival, duration of response, and safety. Tumor response is evaluated using radiological assessments, and safety is assessed through monitoring of adverse events, clinical examinations, and laboratory investigations.
Each cohort is evaluated independently to characterize the activity and tolerability of the respective combination in its treatment setting. The study does not include randomization or a formal comparison between the two cohorts.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Ilya Tsimafeyeu
- 전화번호: +74999054690
- 이메일: bucare@bucare.org
연구 장소
-
-
-
Chelyabinsk, 러시아 제국
- 모병
- Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
-
연락하다:
- Natalia Glushankova
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Krasnoyarsk, 러시아 제국
- 모병
- V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University
-
연락하다:
- Ruslan Zukov
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Orenburg, 러시아 제국
- 모병
- Orenburg Regional Cancer Center
-
연락하다:
- Makhabbat Murzalina
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Saint Petersburg, 러시아 제국
- 모병
- Dr. Berezin Medical Institute
-
연락하다:
- Grigory Raskin
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Saint Petersburg, 러시아 제국
- 모병
- SBHI Leningrad regional clinical hospital, Saint-Petersburg
-
연락하다:
- Andrei Lebedinets
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Saratov, 러시아 제국
- 모병
- Saratov Regional Cancer Center
-
연락하다:
- Svetlana Averianova
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Ufa, 러시아 제국
- 모병
- Republican Clinical Oncology Dispensary
-
연락하다:
- Alexander Sultanbaev
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
Yekaterinburg, 러시아 제국
- 모병
- Sverdlovskiy Regional Oncological Dispensary
-
연락하다:
- Marina Zafirova
- 전화번호: +74999054690
- 이메일: sten_to@mail.ru
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Histologically confirmed chromophobe renal cell carcinoma.
- Measurable disease according to RECIST version 1.1.
- ECOG performance status of 0-3.
- Cohort A: No prior systemic therapy for metastatic disease.
- Cohort B: Disease progression following prior systemic therapy and no previous exposure to lenvatinib
- Adequate bone marrow, hepatic, and renal function.
- Signed informed consent.
Exclusion Criteria:
- Uncontrolled or symptomatic central nervous system metastases or leptomeningeal disease.
- Uncontrolled hypertension despite appropriate antihypertensive treatment.
- Clinically significant uncontrolled cardiovascular disease.
- Active infection requiring systemic treatment.
- Active clinically significant bleeding or a high risk of severe hemorrhage.
- Major surgery without adequate postoperative recovery or a serious non-healing wound.
- Gastrointestinal conditions that significantly impair the absorption of oral study medications.
- Known severe hypersensitivity to any component of the assigned study treatment.
- Current pneumonitis or interstitial lung disease.
- Pregnancy or breastfeeding.
- Any medical or psychiatric condition that, in the investigator's judgment, compromises patient safety or adherence to study procedures.
- Cohort A only: Active autoimmune disease requiring systemic immunosuppressive treatment, or a requirement for chronic systemic immunosuppression, excluding physiological corticosteroid replacement.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Cohort A: first-line lenvatinib plus pembrolizumab
lenvatinib 20 mg orally once daily in combination with pembrolizumab 200 mg intravenously every 3 weeks |
tablets solution |
|
실험적: Cohort B: later-line lenvatinib plus everolimus
lenvatinib 18 mg orally once daily in combination with everolimus 5 mg orally once daily |
tablets tablets |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective response rate
기간: 12 months
|
the proportion of patients achieving a complete or partial response according to RECIST version 1.1 |
12 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
progression-free survival
기간: 24 months
|
the time from treatment initiation to the first documented disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first. |
24 months
|
|
overall survival
기간: 24 months
|
the time from treatment initiation to death from any cause |
24 months
|
|
duration of response
기간: 24 months
|
the time from the first documented complete or partial response to disease progression according to RECIST version 1.1 or death from any cause, whichever occurs first |
24 months
|
|
Grade 3 and higher treatment-emergent adverse events
기간: 24 months
|
the proportion of patients experiencing at least one treatment-emergent adverse event of grade 3 or higher according to NCI CTCAE version 5.0. |
24 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- ChromoKey
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Study results are disseminated through scientific publications and conference presentations in aggregate form.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .